Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Mark Sabag Sells 46,000 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Mark Sabag sold 46,000 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares in the company, valued at $3,386,266.80. The trade was a 36.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Teva Pharmaceutical Industries Stock Up 1.8%

NYSE:TEVA opened at $42.52 on Friday. The stock has a 50-day simple moving average of $39.49 and a 200 day simple moving average of $34.79. Teva Pharmaceutical Industries Ltd. has a one year low of $23.61 and a one year high of $43.34. The company has a market capitalization of $49.55 billion, a price-to-earnings ratio of 98.88, a price-to-earnings-growth ratio of 4.00 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.67 and a current ratio of 0.95.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter last year, the business posted $0.78 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 1.9% compared to the same quarter last year. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares during the period. WCM Investment Management LLC lifted its holdings in Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the period. Wellington Management Group LLP lifted its stake in shares of Teva Pharmaceutical Industries by 5.8% in the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after acquiring an additional 419,329 shares during the period. Janus Henderson Group PLC boosted its stake in Teva Pharmaceutical Industries by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after purchasing an additional 72,880 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in Teva Pharmaceutical Industries by 1.6% during the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock valued at $131,036,000 after buying an additional 70,058 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
• Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
• Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing

Analysts Set New Price Targets

TEVA has been the subject of a number of research reports. Oppenheimer lifted their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday. Zacks Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a research report on Thursday, October 15th. Finally, Leerink Partners lifted their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.23.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.

Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Teva is headquartered in Tel Aviv, Israel.